| Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ... Science 359 (6371), 97-103, 2018 | 3837 | 2018 |
| Evaluation and prognostic significance of circulating tumor cells in patients with non–small-cell lung cancer MG Krebs, R Sloane, L Priest, L Lancashire, JM Hou, A Greystoke, ... Journal of clinical oncology 29 (12), 1556-1563, 2011 | 1050 | 2011 |
| Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer JM Hou, MG Krebs, L Lancashire, R Sloane, A Backen, RK Swain, ... Journal of clinical oncology 30 (5), 525-532, 2012 | 971 | 2012 |
| Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches MG Krebs, JM Hou, R Sloane, L Lancashire, L Priest, D Nonaka, TH Ward, ... Journal of thoracic oncology 7 (2), 306-315, 2012 | 550 | 2012 |
| Circulating tumor cells as a window on metastasis biology in lung cancer JM Hou, M Krebs, T Ward, R Sloane, L Priest, A Hughes, G Clack, ... The American journal of pathology 178 (3), 989-996, 2011 | 521 | 2011 |
| Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response CN Spencer, JL McQuade, V Gopalakrishnan, JA McCulloch, M Vetizou, ... Science 374 (6575), 1632-1640, 2021 | 414 | 2021 |
| A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker L Khoja, A Backen, R Sloane, L Menasce, D Ryder, M Krebs, R Board, ... British journal of cancer 106 (3), 508-516, 2012 | 303 | 2012 |
| The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer A Lallo, KK Frese, CJ Morrow, R Sloane, S Gulati, MW Schenk, F Trapani, ... Clinical Cancer Research 24 (20), 5153-5164, 2018 | 146 | 2018 |
| Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma A Reuben, CN Spencer, PA Prieto, V Gopalakrishnan, SM Reddy, ... NPJ genomic medicine 2 (1), 10, 2017 | 131 | 2017 |
| Circulating biomarkers in hepatocellular carcinoma KL Morris, JD Tugwood, L Khoja, M Lancashire, R Sloane, D Burt, ... Cancer chemotherapy and pharmacology 74, 323-332, 2014 | 78 | 2014 |
| Circulating tumor cells, enumeration and beyond JM Hou, M Krebs, T Ward, K Morris, R Sloane, F Blackhall, C Dive Cancers 2 (2), 1236-1250, 2010 | 70 | 2010 |
| AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer–results of two parallel first-in-human phase I studies A Omlin, RJ Jones, R Van Der Noll, T Satoh, M Niwakawa, SA Smith, ... Investigational new drugs 33, 679-690, 2015 | 55 | 2015 |
| Gene expression profiling of lichenoid dermatitis immune‐related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate … JL Curry, A Reuben, R Szczepaniak‐Sloane, J Ning, DR Milton, CH Lee, ... Journal of cutaneous pathology 46 (9), 627-636, 2019 | 33 | 2019 |
| Interaction of molecular alterations with immune response in melanoma RA Szczepaniak Sloane, V Gopalakrishnan, SM Reddy, X Zhang, ... Cancer 123 (S11), 2130-2142, 2017 | 28 | 2017 |
| Method validation of circulating tumour cell enumeration at low cell counts J Cummings, K Morris, C Zhou, R Sloane, M Lancashire, D Morris, ... BMC cancer 13, 1-8, 2013 | 22 | 2013 |
| Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells J Cummings, R Sloane, K Morris, C Zhou, M Lancashire, D Moore, T Elliot, ... BMC cancer 14, 1-8, 2014 | 14 | 2014 |
| Multi-modal molecular programs regulate melanoma cell state MC Andrews, J Oba, CJ Wu, H Zhu, T Karpinets, CA Creasy, MA Forget, ... Nature communications 13 (1), 4000, 2022 | 10 | 2022 |
| Identification of microRNA–mRNA networks in melanoma and their association with PD-1 checkpoint blockade outcomes RAS Sloane, MG White, RG Witt, A Banerjee, MA Davies, G Han, E Burton, ... Cancers 13 (21), 5301, 2021 | 8 | 2021 |
| Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med A Reuben, CN Spencer, PA Prieto, V Gopalakrishnan, SM Reddy, ... | 8 | 2017 |
| Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma MG White, R Szczepaniak Sloane, RG Witt, A Reuben, PO Gaudreau, ... Oncoimmunology 10 (1), 1992880, 2021 | 6 | 2021 |
